Clodronate as a Single-dose Intravenous Infusion Effectively Provides Short-term Correction of Malignant Hypercalcemia

The efficacy and safety of a single intravenous (I.V.) infusion of clodronate 1 500 mg or 900 mg was compared with a single I.V. infusion of pamidronate 90 mg in the treatment of malignant hypercalcemia. Primary efficacy data from two separate, but parallel, randomized double-blind controlled multi-...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2003-11, Vol.42 (7), p.735-740
Main Authors: Atula, Sari T., Tähtelä, Riitta K., Nevalainen, Jaakko I., Pylkkänen, Liisa H.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Calcium - blood
Clodronic Acid - therapeutic use
Diphosphonates - therapeutic use
Double-Blind Method
Female
General and cellular metabolism. Vitamins
Humans
Hypercalcemia - drug therapy
Hypercalcemia - etiology
Infusions, Intravenous
Male
Medical sciences
Middle Aged
Neoplasms - complications
Pamidronate
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy and safety of a single intravenous (I.V.) infusion of clodronate 1 500 mg or 900 mg was compared with a single I.V. infusion of pamidronate 90 mg in the treatment of malignant hypercalcemia. Primary efficacy data from two separate, but parallel, randomized double-blind controlled multi-center studies (N=63), involving patients with malignant hypercalcemia (S-Cacor>2.68 mmol/l), were pooled along with results from a study (N=4), in which an open I.V. phase was followed by a randomized oral phase. The primary efficacy variable, the proportion of normocalcemic patients at day 5 could be evaluated from 51 subjects. Of them, 21 were in the clodronate 1 500 mg group, 10 in the clodronate 900 mg group and 20 in the pamidronate 90 mg group. After the rehydration, the patients were given a single I.V. infusion of clodronate 1 500 mg, clodronate 900 mg or pamidronate 90 mg. The patients were followed up for five days and S-Cacorwas measured daily. At day 5, a total of 16 patients (76%) in the clodronate 1 500 mg group, six patients (60%) in the clodronate 900 mg group and 17 patients (85%) in the pamidronate 90 mg group were normocalcemic, the differences between the treatment groups being statistically non-significant. The differences in the mean S-Cacorbetween the treatment groups were statistically non-significant. I.V. clodronate given either as 900 mg or 1 500 mg single-dose was safe and well tolerated.
ISSN:1103-8128
0284-186X
1651-2014
1651-226X
DOI:10.1080/02841860310013111